Navigating Bridging Therapy With CAR T-Cell Therapy in Multiple Myeloma

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss key considerations when selecting and managing bridging therapy prior to CAR T-cell infusion in multiple myeloma. They examine how disease burden, prior treatments, and manufacturing timelines influence bridging strategy choices. Merz and Bellerive emphasize balancing disease control with preservation of T-cell fitness ahead of infusion.